BBIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

148.12M

+2418.14%

-0.663

-52.68%

167.54M

+43.65%

-0.651

-26.02%

194.33M

+75.76%

-0.552

-41.89%

Estimates Revision

The market is revising Upward the revenue expectations for BridgeBio Pharma, Inc. (BBIO) for FY2025, with the revenue forecasts being adjusted by 4.68% over the past three months. During the same period, the stock price has changed by 38.05%.

Revenue Estimates for FY2025

Revise Upward

+4.68%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.76%

In Past 3 Month

Stock Price

Go Up

+38.05%

In Past 3 Month

16 Analyst Rating

Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 84.20 USD with a low forecast of 64.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

64.00

Averages

84.20

High

100.00

Current: 0.000

Low

64.00

Averages

84.20

High

100.00

Raymond James

Outperform

initiated

$24

2026-01-09

New

Reason

Raymond James

Price Target

$24

2026-01-09

New

initiated

Outperform

Reason

Raymond James initiated coverage of BridgeBio Oncology with an Outperform rating and $24 price target. The rating reflects promising early Phase 1 activity and safety for BBO-8520 in 1L Non-Small Cell Lung Cancer, potent and selective inhibition by pan-KRAS BBO-11818, potential differentiation of BBO-10203 in metastatic breast cancer, and strong capitalization to advance proof-of-concept updates for all assets, the analyst tells investors in a research note. Confidence is tempered by crowded competition in the KRAS inhibitor space, the firm adds.

Morgan Stanley

Overweight

downgrade

$20 -> $18

2026-01-08

New

Reason

Morgan Stanley

Price Target

$20 -> $18

2026-01-08

New

downgrade

Overweight

Reason

Morgan Stanley lowered the firm's price target on BridgeBio Oncology to $18 from $20 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Leerink

Outperform

maintain

$75 -> $86

2025-12-15

Reason

Leerink

Price Target

$75 -> $86

2025-12-15

maintain

Outperform

Reason

Leerink raised the firm's price target on BridgeBio to $86 from $75 and keeps an Outperform rating on the shares. Heading into 2026, the firm is refreshing its TTR market outlook after strong launches from BridgeBio's (BBIO) Attruby and Alnylam's (ALNY) Amvuttra. Leerink expects continued robust growth in 2026, supported by end-market tailwinds from improved diagnosis rates leading to earlier treatment, but is keeping tabs on payer/reimbursement dynamics and pace of new patient adds/switches.

Wells Fargo

Overweight

maintain

$76 -> $84

2025-11-11

Reason

Wells Fargo

Price Target

$76 -> $84

2025-11-11

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on BridgeBio to $84 from $76 and keeps an Overweight rating on the shares. The firm likes the setup for shares, as it thinks there is likely upside to Attruby estimates in 2026, potential to gain clarity on Tafamidis Gxs, which should remove a key overhang, and a high probability of success Phase 3 read out for infigratinib in achondroplasia in early 2026.

JPMorgan

Anupam Rama

maintain

$76 -> $77

2025-11-07

Reason

JPMorgan

Anupam Rama

Price Target

$76 -> $77

2025-11-07

maintain

Reason

JPMorgan analyst Anupam Rama raised the firm's price target on BridgeBio to $77 from $76 and keeps an Overweight rating on the shares. The firm updated the company's model.

Goldman Sachs

Buy

upgrade

$55 -> $100

2025-10-31

Reason

Goldman Sachs

Price Target

$55 -> $100

2025-10-31

upgrade

Buy

Reason

Goldman Sachs raised the firm's price target on BridgeBio to $100 from $55 and keeps a Buy rating on the shares. BridgeBio's Q3 results highlighted strong commercial momentum for Attruby, with U.S. sales of $108.1M, exceeding estimates and reflecting a 40% increase in prescriptions since August, the analyst tells investors in a research note. Management cited growing share among newly diagnosed ATTR-CM patients and reiterated a 30%-35% target, supported by continued investment in awareness and diagnosis expansion. With topline results from the PROPEL 3 achondroplasia study expected in early 2026 and a deepening commercial pipeline, BridgeBio's transition toward a multi-product, profitable biotech remains on track, offering further upside potential, the firm says.

Valuation Metrics

The current forward P/E ratio for BridgeBio Pharma Inc (BBIO.O) is -33.67, compared to its 5-year average forward P/E of -9.80. For a more detailed relative valuation and DCF analysis to assess BridgeBio Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.80

Current PE

-33.67

Overvalued PE

-3.26

Undervalued PE

-16.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.98

Current EV/EBITDA

-70.17

Overvalued EV/EBITDA

-3.16

Undervalued EV/EBITDA

-28.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

82.91

Current PS

20.57

Overvalued PS

158.64

Undervalued PS

7.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areBuying! The buying amount has increased100%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BBIO News & Events

Events Timeline

No data

News

4.0

01-06CNBC

Morgan Stanley Initiates Belite Bio at Overweight with $191 Price Target

1.0

01-02Globenewswire

BridgeBio to Host Investor Webinar on Achondroplasia Treatment Insights

4.5

2025-12-31Barron's

U.S. Markets Declined on Wednesday; QXO Experienced the Largest Drop

People Also Watch

Frequently Asked Questions

What is BridgeBio Pharma Inc (BBIO) stock price today?

The current price of BBIO is 77.25 USD — it has increased 4.65 % in the last trading day.

What is BridgeBio Pharma Inc (BBIO)'s business?

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

What is the price predicton of BBIO Stock?

What is BridgeBio Pharma Inc (BBIO)'s revenue for the last quarter?

BridgeBio Pharma Inc revenue for the last quarter amounts to 120.70M USD, increased 4318.01 % YoY.

What is BridgeBio Pharma Inc (BBIO)'s earnings per share (EPS) for the last quarter?

BridgeBio Pharma Inc. EPS for the last quarter amounts to -0.95 USD, increased 10.47 % YoY.

What changes have occurred in the market's expectations for BridgeBio Pharma Inc (BBIO)'s fundamentals?

How many employees does BridgeBio Pharma Inc (BBIO). have?

BridgeBio Pharma Inc (BBIO) has 725 emplpoyees as of January 11 2026.

What is BridgeBio Pharma Inc (BBIO) market cap?

Today BBIO has the market capitalization of 14.89B USD.